Literature DB >> 8329147

Drug-induced male sexual dysfunction. An update.

G B Brock1, T F Lue.   

Abstract

Impotence, defined as the consistent inability to maintain an erect penis of sufficient rigidity for sexual intercourse, has been estimated to affect 10 million American men. An age dependence has been shown to exist, with 25% of men over age 65 affected. A large body of clinical experience and published reports in the literature link many commonly prescribed drugs with sexual dysfunction. Drugs can affect sexual function at a variety of points such as inhibition of ejaculation or sedation/depression leading to reduced libido. Antihypertensive drugs have been most commonly associated with impotence. There have been reports of sexual dysfunction with almost all classes of antipsychotics, but little clinical investigation has been performed. Other drugs associated with sexual dysfunction include digoxin, clofibrate, cimetidine and various hormonal agents and antineoplastics. An important first step in approaching all impotent patients is the taking of a detailed medical, surgical, sexual and drug/substance abuse history. The least invasive form of therapy should be employed. Recent studies have shown intracavernous injections of alprostadil (prostaglandin E1) to be safe and effective for long term use. Vacuum constriction devices may also be of help. Better and more durable prostheses are now available should other treatment be unsuccessful.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329147     DOI: 10.2165/00002018-199308060-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  71 in total

1.  Acute vasospasm of penile arteries in response to cigarette smoking.

Authors:  L A Levine; G S Gerber
Journal:  Urology       Date:  1990-07       Impact factor: 2.649

2.  Effects of regular marijuana use on sexual performance.

Authors:  J Halikas; R Weller; C Morse
Journal:  J Psychoactive Drugs       Date:  1982 Jan-Jun

3.  Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence.

Authors:  M P Rosen; A J Greenfield; T G Walker; P Grant; J Dubrow; M A Bettmann; L E Fried; I Goldstein
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

4.  Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension.

Authors:  J W Hollifield; K Sherman; R V Zwagg; D G Shand
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

5.  Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration.

Authors:  G R Fournier; K P Juenemann; T F Lue; E A Tanagho
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

6.  Impotence in medical clinic outpatients.

Authors:  M F Slag; J E Morley; M K Elson; D L Trence; C J Nelson; A E Nelson; W B Kinlaw; H S Beyer; F Q Nuttall; R B Shafer
Journal:  JAMA       Date:  1983-04-01       Impact factor: 56.272

Review 7.  A review of alcohol's effects on sex and reproduction.

Authors:  E L Abel
Journal:  Drug Alcohol Depend       Date:  1980-05       Impact factor: 4.492

Review 8.  The use and misuse of androgens.

Authors:  J D Wilson; J E Griffin
Journal:  Metabolism       Date:  1980-12       Impact factor: 8.694

9.  Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection.

Authors:  E Willis; B Ottesen; G Wagner; F Sundler; J Fahrenkrug
Journal:  Acta Physiol Scand       Date:  1981-12

10.  Fibroadenomatoid hyperplasia of the male breast.

Authors:  B B Nielsen
Journal:  Am J Surg Pathol       Date:  1990-08       Impact factor: 6.394

View more
  8 in total

Review 1.  Erectile dysfunction in hemodialysis: A systematic review.

Authors:  Ahmed El-Assmy
Journal:  World J Nephrol       Date:  2012-12-06

Review 2.  Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator.

Authors:  H Solomon; J W Man; G Jackson
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

Review 3.  Erectile dysfunction: management update.

Authors:  Luke Fazio; Gerald Brock
Journal:  CMAJ       Date:  2004-04-27       Impact factor: 8.262

Review 4.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

5.  Nitric oxide as a mediator of cocaine-induced penile erection in the rat.

Authors:  J Y Chan; C L Huang; S H Chan
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 6.  Sexual function in hypertensive patients receiving treatment.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Vasc Health Risk Manag       Date:  2006

7.  A Nationwide Population-Based Cohort Study of Migraine and Organic-Psychogenic Erectile Dysfunction.

Authors:  Szu-Hsien Wu; Eric Chuang; Tien-Yow Chuang; Cheng-Li Lin; Ming-Chia Lin; Der-Jen Yen; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Vardenafil Oral Dispersible Films (ODFs) with Advanced Dissolution, Palatability, and Bioavailability.

Authors:  Heba A Abou-Taleb; Wesam W Mustafa; Tarek Saad Makram; Lamiaa N Abdelaty; Hesham Salem; Hamdy Abdelkader
Journal:  Pharmaceutics       Date:  2022-02-26       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.